Physician profile
Ravi Ramani
NPI 1164497640
$3,646.26
in general payments reported to CMS, 2019-2025
25 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $125 · 2021: $54.51 · 2022: $283 · 2023: $782 · 2024: $685 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487 · Travel and Lodging: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.98 |
| Travel and Lodging | $571.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,224.96 | 2023-2025 | Evoque, Pascal |
| Medtronic, INC. | $624.93 | 2023-2025 | Avalus, Onyx Frontier, Octopus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.71 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $249.90 | 2019-2020 | |
| Abbott Laboratories | $232.93 | 2022-2024 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $202.16 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $135.20 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $109.96 | 2021-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $90.75 | 2025 | Attruby |
| Pfizer INC. | $88.68 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $75.14 | 2023-2024 | Inpefa |
| Abiomed | $62.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.15 | 2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $22.61 | 2022 | |
| Astellas Pharma US INC | $22.12 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.98 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.71 | 2024 | Xarelto |
| Atricure, INC. | $16.96 | 2023 | |
| Genzyme Corporation | $15.89 | 2021 | |
| Novo Nordisk INC | $15.66 | 2024 | Rybelsus, Ozempic |
| Impulse Dynamics (USA) INC. | $15.37 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $14.86 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $14.53 | 2022 | |
| Amgen INC. | $13.45 | 2023 | Repatha |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Ramani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.